Evidence mapPaperPMID 37979099Full record

ArticleEndocrine2024

The endocrine disruptor cadmium modulates the androgen-estrogen receptors ratio and induces inflammatory cytokines in luminal (A) cell models of breast cancer.

Viviana M Bimonte, Giuseppina Catanzaro, Agnese Po, Sofia Trocchianesi, Zein Mersini Besharat, Zaira Spinello, Mariaignazia Curreli, Alessandra Fabi, Roberto Bei, Michele Milella and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Viviana M Bimonte *Department of Movement, Human and Health Sciences, University of Foro Italico, 00195, Rome, Italy.
Giuseppina Catanzaro *Department of Experimental Medicine, "Sapienza" University of Rome, 00161, Rome, Italy.
Agnese PoDepartment of Molecular Medicine, "Sapienza" University of Rome, 00161, Rome, Italy.
Sofia TrocchianesiDepartment of Molecular Medicine, "Sapienza" University of Rome, 00161, Rome, Italy.
Zein Mersini BesharatDepartment of Experimental Medicine, "Sapienza" University of Rome, 00161, Rome, Italy.
Zaira SpinelloDepartment of Experimental Medicine, "Sapienza" University of Rome, 00161, Rome, Italy.
Mariaignazia CurreliDepartment of Movement, Human and Health Sciences, University of Foro Italico, 00195, Rome, Italy.
Alessandra FabiPrecision Medicine in Senology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168, Rome, Italy.
Roberto BeiDepartment of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133, Rome, Italy.
Michele MilellaDepartment of Oncology, University of Verona, 37134, Verona, Italy.
Alessandra VaccaDepartment of Experimental Medicine, "Sapienza" University of Rome, 00161, Rome, Italy.
Elisabetta Ferretti *Department of Experimental Medicine, "Sapienza" University of Rome, 00161, Rome, Italy.
Silvia Migliaccio *Department of Movement, Human and Health Sciences, University of Foro Italico, 00195, Rome, Italy. silvia.migliaccio@uniroma4.it.ORCID 0000-0002-4563-6630
Sapienza University of Rome · ITForo Italico University of Rome · ITAgostino Gemelli University Polyclinic · ITUniversity of Rome Tor Vergata · ITUniversity of Verona · IT

Funding

Ministero dell'Istruzione, dell'Università e della Ricerca PON ARS01 00693Ministero dell'Università e della Ricerca PRIN 20205HZBP8
6 · The paper itself

Abstract

purposeBreast cancer (BC) is the most common malignancy that affects women, and it is, to date, their leading cause of death. Luminal A molecular subtype accounts for 40% of BC and is characterized by hormone receptors positive/human epidermal growth factor 2 expression and current treatment consists of surgery plus aromatase inhibitor therapy. Interestingly, several studies demonstrated that the heavy metal cadmium (Cd), classified as a group 1 human carcinogen and widely spread in the environment, exerts estrogen-like activities in several tissues and suggested an intriguing relationship between increased Cd exposure and BC incidence. Thus, aim of this study was to evaluate effects of Cd on Luminal A BC estrogen receptor (ER) positive/progesterone receptor positive cell models in vitro to characterize the mechanism(s) involved in breast cell homeostasis disruption.

methodsT47D and MCF7 were exposed to Cd (0.5-1 µM) for 6-24 h to evaluate potential alterations in: cells viability, steroid receptors and intracellular signaling by western blot. Moreover, we evaluated the expression of inflammatory cytokines interleukin by RT-PCR.

resultsOur results showed a significant induction of androgen receptor (AR) and an increased AR/ER ratio. Further, Cd exposure increased pro-inflammatory cytokines interleukin (IL)6, IL8 and tumor necrosis factor α levels. Finally, as previously demonstrated by our group, Cd alters pathways such as mitogen-activated protein kinase family and protein kinase B.

conclusionIn conclusion, our study demonstrates that Cd modifies the expression and pattern of ERs and AR in BC cell lines, suggesting an alteration of BC cells homeostasis, likely predisposing to a carcinogenetic microenvironment.

Indexed as

Breast NeoplasmsEndocrine DisruptorsAndrogensCadmiumCell Line, TumorCytokinesEstrogensFemaleHumansInterleukin-6Receptors, AndrogenReceptors, EstrogenTumor MicroenvironmentAndrogensCadmiumCytokinesEndocrine DisruptorsEstrogensInterleukin-6Receptors, AndrogenReceptors, EstrogenAndrogen receptorBreast cancerCadmiumCytokinesEndocrine disruptorsEstrogen receptors

Identifiers

PMID37979099
PMCPMC10902028
OpenAlexW4388797335

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.